KaydedilenlerDerginizi ekleyin

Dergiler / Eurasian Journal of Medicine / 2011 / Cilt: 43 - Sayı: 3

Evaluation of peripheral blood smear for myelodysplasia in breast cancer patients who received adjuvant antracycline

Adjuvan antrasiklin rejimi almış remisyondaki meme kanserli hastalarda myelodisplazi açısından periferik yayma değerlendirmesi

ÜSKÜDAR Havva TEK
Hediye UĞUR
Zeki AKÇA
Hasan MUTLU
Sayfa
173–176
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Bulgular: İki hastada anemi (%2.2) (Hb

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Amaç: Tedaviye bağlı myeloid neoplazmlar, tüm AML,MDS ve MDS/ MPN vakalrının yaklaşık %10-20’sini oluşturmaktadır.
📊
Temel Bulgular & Veri:Çalışmamızda adjuvant antrasiklinli kemoterapi rejimi almış remisyonda meme kanserli hastaların periferik yayma ve hemogram değerlerini araştırılmıştır.
💡
Sonuç & Katkı:Bulgular: İki hastada anemi (%2.2) (Hb
🔬Tür:Araştırma Makalesi
📍Kapsam:78 hasta
⚙️Değişkenler:Alan Parametreleri

Özet

Amaç: Tedaviye bağlı myeloid neoplazmlar, tüm AML,MDS ve MDS/ MPN vakalrının yaklaşık %10-20’sini oluşturmaktadır. Çalışmamızda adjuvant antrasiklinli kemoterapi rejimi almış remisyonda meme kanserli hastaların periferik yayma ve hemogram değerlerini araştırılmıştır. Gereç ve Yöntem: Antrasiklin bazlı kemoterapi rejimi almış ve remisyonda olan toplam 78 hasta Kayseri Eğitim ve Araştırma Hastanesi ile Mersin Devlet Hastanesi’nden çalışmaya alınmıştır. Hastaların remisyonda olması ve tedaviyi en az 18 ay once tamamlamış olmasına dikkat edildi. Bulgular: İki hastada anemi (%2.2) (Hb

Abstract

Objective: Therapy-related myeloid neoplasms (t-MN) account for approximately 10% to 20% of all cases of AML (acute myeloid leukemia), MDS (myelodysplastic syndrome) and MDS/MPN (myelodysplastic syndrome/myeloproliferative neoplasms), MDS, and MDS/MPN. In our study, we evaluated peripheral blood smear samples and hemogram values in breast cancer patients who were receiving adjuvant anthracycline regimens and were in remission. Materials and Methods: A total of 78 patients receiving anthracycline- based adjuvant chemotherapy treatment from Kayseri Research and Training Hospital and Mersin State Hospital were enrolled in the study. Their adjuvant treatments had been completed at least 18 months prior to the study. Results: Two patients complained of anemia (2.2%) (Hb

🔖

Bu Makaleye Atıf Yap

TEK, Ü. H., UĞUR, H., AKÇA, Z., MUTLU, H. (2022). Evaluation of peripheral blood smear for myelodysplasia in breast cancer patients who received adjuvant antracycline. Eurasian Journal of Medicine, Cilt: 43 - Sayı: 3, 173–176. https://ajindex.com/articles/509254

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001
  2. [CrossRef] 2. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 1998
  3. Zujewski J, Liu ET. The 1998 St. Gallen’s Consensus Conference: An assessment. J Natl Cancer Inst 1998
  4. Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998
  5. Le Deley MC, Suzan F, Cutuli B, et al. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol 2007
  6. Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 1992
  7. Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst 2008
  8. Bernard-Marty C, Mano M, Paesmans M, et al. Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients. Ann Oncol 2003
  9. Cutuli B, Janvier M, de la Rochefordière A, et al. Leukemia and pre-leukemic conditions occurring after treatment of breast cancer. Presse Med 2000
  10. Chaplain G, Milan C, Sgro C, Carli PM, Bonithon-Kopp C. Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study. J Clin Oncol 2000
  11. Linassier C, Barin C, Calais G, et al. Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy. Ann Oncol 2000
  12. Smith RE, Bryant J, DeCillis A, Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 2003
  13. Rowley JD, Golomb HM, Vardiman JW. Nonrandom chromosome abnormalities in acu